drugset / Trial / NCT02448732

Exploratory Clinical Trials of ACM-1 in the Treatment of Ophthalmological Neovascular Diseases

NCT02448732 ↗

Phase 0 Unknown 10 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the role of intravitreal injection of anti-vascular endothelial growth factor (VEGF) therapy in prevention and control of ophthalmological neovascular diseases, in order to find a new strategy of treatment for ophthalmological neovascular diseases

Timeline

Start
2014-12
Primary completion
2016-04
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject ACM-1 Unknown 1600 ug/ml Intravitreal